The biologic treatment Stelara (Ustekinumab) is now available for the treatment of moderate-to-severe plaque psoriasis in adolescents age 12 years and older who have not responded to or are intolerant to other systemic therapies or phototherapies.
Psoriasis is an inflammatory skin condition affecting about 2% of the population, which is characterised by red and scaly plaques.
Stelara is an 45 mg or 90 mg injection given under the skin administered by a healthcare provider or self-injected after training.
The European Commission gave approval in June following the study results of patients aged 12-17 years who were treated with Ustekinumab.
Ustekinumab has been beneficial in the management of adult psoriasis for many years, so this is a positive addition to the treatment options for young adults suffering from severe plaqua psoriasis who are not responding to, or are intolerant to other systemic therapies or phototherapies.
You can find more information about Stelara here.
The Dermatologists at The London Skin and Hair Clinic diagnose psoriasis and treat patients with a full range of treatment options including biologics such as a Stelara (Ustekinumab). Contact the clinic for further information.